Kodjikian, Laurent http://orcid.org/0000-0002-3908-6716
Arias Barquet, Lluís
Papp, András
Kertes, Peter J. http://orcid.org/0000-0002-0348-5096
Midena, Edoardo
Ernest, Jan
Silva, Rufino http://orcid.org/0000-0001-8676-0833
Schmelter, Thomas http://orcid.org/0000-0003-1358-3172
Niesen, Tobias
Leal, Sergio
Clinical trials referenced in this document:
Documents that mention this clinical trial
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing
https://doi.org/10.1007/s12325-023-02719-3
Funding for this research was provided by:
Bayer
Article History
Received: 20 July 2023
Accepted: 23 October 2023
First Online: 6 January 2024
Declarations
:
: Laurent Kodjikian: Consultant for AbbVie/Allergan, Alimera/Horus, Bayer, Novartis, Roche, and Thea. Lluís Arias Barquet: Consultant for Allergan, Bayer, Novartis, Roche, and Topcon. András Papp: Consultant for Bayer, Novartis, and Roche; received travel grants from Novartis; and his department has been involved in the conduct of several studies sponsored by Novartis, Bayer, Ophthotech/Iveric Bio, Samsung Bioepis, Oculis, Amgen, Qilu, Chengdu Kanghong, Roche, PanOptica, Xbrane, Genentech, Bioeq, Allergan, ThromboGenics, Regeneron, and Clearside Biomedical. Peter J. Kertes: Honoraria: Novartis, Bayer, Roche, Boehringer Ingelheim, Pfizer, and Zeiss; Advisory board: Novartis, Bayer, Roche, and Novelty Nobility; Financial support (to institution): Roche, Novartis; Equity owner: ArcticDx. Edoardo Midena: Served as a steering committee member for Bayer. Jan Ernest: Nothing to disclose. Rufino Silva: Advisory Board: AbbVie, Alimera, Bayer, Novartis, Thea, Roche, and Novo Nordisk. Thomas Schmelter: Employee of Bayer. Tobias Niesen: Employee of Bayer. Sergio Leal: Employee of Bayer. No authors of this manuscript have any proprietary interests.
: The study was conducted at 64 sites in Europe and Canada from September 2015 to June 2020, in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines E6: Good Clinical Practice. The study protocol and statistical analysis plan can be accessed at ClinicalTrials.gov (identifier: NCT02540954). The protocol was approved by the independent ethics committee or institutional review board at each study site. All patients provided written informed consent.